Literature DB >> 27634644

Proposal of a Dukes-MAC-like staging system for gastric cancer.

Simona Gurzu1, Haruhiko Sugimura2, Janina Orlowska3, Janos Szederjesi4, Zoltan Szentirmay5, Tivadar Bara6, Tivadar Bara6, Ananmaria Fetyko1, Ioan Jung1.   

Abstract

The aim of this study was to present an epidemiological update regarding the classical prognostic parameters of gastric cancer (GC) in 3 countries from Eastern Europe and to suggest a modification of the pTNM staging system. In 333 consecutive cases which were diagnosed between 2003 and 2012 in 3 departments of pathology from Romania, Hungary, and Poland, the following parameters were analyzed: age and gender of patients, tumor localization, macroscopic and microscopic aspects including the degree of discohesivity, depth of tumor infiltration, and pTNM stage. From all of the studied parameters, the following proved to have independent prognostic value, indicating a lower survival rate: presence of distant metastases (p=0.001), lymph node positivity (p=0.0009), depth of tumor infiltration (p=0.04), age over 50 (p=0.02), proximally located tumors (p=0.03), and ulceroinfiltrative or diffusely infiltrative macroscopic aspect (p=0.0002). The pT2N1-3 staged cases showed a worse prognosis compared with the pT3N0 ones (p=0.02). Regardless of depth of invasion, the lymph node status remains the strongest indicator of the survival rate in GC. The pTN staging system should be adapted and a Dukes-MAC-like staging system should include the following groups: stage A1-T1N0, stage A2-T1N1-3, stage B1-T2N0, stage B2-T2N1-3, stage C1-T3N0, stage C2-T3N1-3, and stage D-T4N0-3. The grade of discohesivity/budding is not a prognostic factor in GC.
Copyright © 2016 American Federation for Medical Research.

Entities:  

Keywords:  Cancer; Carcinoma; Interdisciplinary Studies; Stomach

Mesh:

Year:  2016        PMID: 27634644     DOI: 10.1136/jim-2016-000270

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  5 in total

1.  HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial Antibodies.

Authors:  Catalin Bogdan Satala; Ioan Jung; Raluca Ioana Stefan-van Staden; Zsolt Kovacs; Calin Molnar; Tivadar Bara; Zsolt Zoltan Fulop; Simona Gurzu
Journal:  J Oncol       Date:  2020-10-20       Impact factor: 4.375

2.  Gastrointestinal Carcinoma with Plasmacytoid Morphology: Positivity for c-MET, Arylsulfatase, and Markers of Epithelial-Mesenchymal Transition, as Indicators of Aggressivity.

Authors:  Zsolt Kovacs; Simona Gurzu; Calin Molnar; Mihaela Sincu; Laura Banias; Catalin Satala; Ioan Jung
Journal:  J Oncol       Date:  2019-05-08       Impact factor: 4.375

3.  The Effects of Resistin Gene Polymorphism on Pain Thresholds and Postoperative Sufentanil Consumption in Gastric Cancer Patients.

Authors:  Jianing Li; Shuo Li; Ling Yu; Jin Wei; Shuang Li; Hongyu Tan
Journal:  J Pain Res       Date:  2022-07-17       Impact factor: 2.832

4.  V-set and immunoglobulin domain containing 1 (VSIG1) as an emerging target for epithelial-mesenchymal transition of gastric cancer.

Authors:  Catalin-Bogdan Satala; Ioan Jung; Zsolt Kovacs; Raluca-Ioana Stefan-Van Staden; Calin Molnar; Tivadar Bara; Andrei-Ionut Patrichi; Simona Gurzu
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

5.  The RNA-Binding Protein NELFE Promotes Gastric Cancer Growth and Metastasis Through E2F2.

Authors:  Changyu Chen; Qiang Zheng; Shubo Pan; Wenzheng Chen; Jianfeng Huang; Yi Cao; Yi Tu; Zhengrong Li; Changjun Yu; Zhigang Jie
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.